Literature DB >> 9617764

The putative 116 kDa osteoclast specific vacuolar proton pump subunit has ubiquitous tissue distribution.

B B Scott1, C G Chapman.   

Abstract

The pharmacological profile of the osteoclast proton pump has been demonstrated to be unique and to be the most active of all acid transport systems thus far studied. The recently reported putative 116 kDa osteoclast specific vacuolar proton pump subunit could possibly explain the unique nature of this proton pump. Here, we demonstrate however, that the osteoclast 116 kDa subunit is not osteoclast specific but has ubiquitous expression in human tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9617764     DOI: 10.1016/s0014-2999(98)00163-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.

Authors:  L Visentin; R A Dodds; M Valente; P Misiano; J N Bradbeer; S Oneta; X Liang; M Gowen; C Farina
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.

Authors:  Kazuaki Niikura; Mikiko Takano; Masae Sawada
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

3.  Epiregulin (EREG) and human V-ATPase (TCIRG1): genetic variation, ethnicity and pulmonary tuberculosis susceptibility in Guinea-Bissau and The Gambia.

Authors:  M J White; A Tacconelli; J S Chen; C Wejse; P C Hill; V F Gomes; D R Velez-Edwards; L J Østergaard; T Hu; J H Moore; G Novelli; W K Scott; S M Williams; G Sirugo
Journal:  Genes Immun       Date:  2014-06-05       Impact factor: 2.676

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.